Business Context and Reporting Period
This Form 8-K reports on the 2021 Annual Meeting of Stockholders held by Pavmed Inc. on June 15, 2021. The company is an emerging growth company incorporated in Delaware, with its principal executive offices in New York. The filing details the outcomes of shareholder votes regarding director elections and amendments to equity incentive plans.
Key Financial Metrics
This filing is a current report regarding corporate governance and does not contain financial statements. Consequently, data regarding revenue, profit, cash flow, margins, debt, and liquidity are not provided in this document.
Material Changes and Corporate Actions
- Board Composition: The board size was reduced from seven to six members following the expiration of David Weild IV's term. Two Class B directors, James L. Cox, M.D., and Debra J. White, were re-elected.
- 2014 Long-Term Incentive Equity Plan Amendment: Shareholders approved increasing the share reserve by 2,000,000 shares (to 11,951,081 total) and adding an "evergreen" provision to automatically increase shares by 5% of outstanding stock annually. The limit on grants to individual participants was removed for employees (non-employee director limits remain).
- Employee Stock Purchase Plan (ESPP) Amendment: Shareholders approved increasing the authorized shares by 500,000 (to 1,250,000 total) and adding an "evergreen" provision to increase shares by the lesser of 2% of outstanding stock or 2,500,000 shares annually.
- Auditor Ratification: Marcum LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2021.
Guidance, Outlook, and Risks
The filing does not contain management guidance, financial outlook, or specific risk factors. The primary focus is the ratification of corporate governance matters. The approval of the "evergreen" provisions in the equity plans introduces a mechanism for future dilution, which is a standard consideration for investors regarding equity-based compensation.
Investor Verification Checklist
- Verify the exact number of shares outstanding as of December 31, 2020, to calculate the impact of the new 5% and 2% "evergreen" provisions on future share counts.
- Review the full text of the Fifth Amended and Restated 2014 Long-Term Incentive Equity Plan (Exhibit 10.1) to understand specific vesting schedules and grant limitations.
- Confirm the total number of shares currently reserved for issuance under both the 2014 Plan and the ESPP to assess potential dilution.
- Check subsequent filings for the actual issuance of shares under the newly amended plans.